Cointime update: Akeso’s Hong Kong-listed shares fell 15% after its US partner’s new drug failed to win FDA approval. The decline followed the regulatory rejection of the partner company’s drug candidate. Akeso’s Hong Kong shares dropped 15% on the news.
Akeso’s Hong Kong Shares Fall 15% After Partner’s Drug Fails FDA Approval
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
11m ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%
46m ago
JPMorgan Keeps Zhipu at Overweight, HK$1,200 Target
51m ago
Morgan Stanley’s Wilson: Nvidia Q3 Results Broadly In Line, AI Still Worth Investing
1h ago
Nvidia beats estimates; analysts flag lingering uncertainty over outlook
2h ago
Binance to Launch USDT Perpetual Contracts for Six TradFi Assets
6h ago
Anthropic Expected to Price IPO Above Range at $80+ Per Share